PUBLICATION

Dissecting Oncogenic RAS Signaling in Melanoma Development in Genetically Engineered Zebrafish Models

Authors
Badrock, A.P., Hurlstone, A.
ID
ZDB-PUB-210513-5
Date
2021
Source
Methods in molecular biology (Clifton, N.J.)   2262: 411-422 (Chapter)
Registered Authors
Hurlstone, Adam
Keywords
CRISPR, Microinjection, RAS, Tol2, Transgenic, Zebrafish
MeSH Terms
  • Animals
  • Animals, Genetically Modified
  • Cell Transformation, Neoplastic/genetics
  • Cell Transformation, Neoplastic/metabolism
  • Cell Transformation, Neoplastic/pathology*
  • Disease Models, Animal*
  • Humans
  • Melanoma/genetics
  • Melanoma/metabolism
  • Melanoma/pathology*
  • Mutation*
  • Transgenes/genetics*
  • Zebrafish
  • ras Proteins/genetics
  • ras Proteins/metabolism*
PubMed
33977492 Full text @ Meth. Mol. Biol.
Abstract
Hyper-activation of RAS signaling pathways causes cancer, including melanoma, and RAS signaling pathways have been successfully targeted using drugs for patient benefit. The available drugs alone cannot cure cancer, however, and so investigation continues into RAS signaling pathways, with the goal of identifying further actionable targets. The zebrafish can be used to model human malignancies, and genetic modification of zebrafish to incorporate selective disease-associated genetic alterations is practicable. The following article describes the methods we are using to genetically modify zebrafish in order to dissect oncogenic RAS signaling in melanoma development.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping